Clinical Trials Update from NCI, November 2018

Clinical Trials Update from NCI, November 2018

Clinical Trials
Updates from the National Cancer Institute
Clinical Trials News
		Tailored Radiation to Treat Brain Metastases Reduces Impact on Cognitive Function Results from a clinical trial suggest that, in patients with brain metastases, an advanced radiotherapy technique can limit harm to patients’ cognitive function without affecting the treatment’s effect on tumors.
		Olaparib after Initial Treatment Delays Ovarian Cancer Progression In a recent trial, the PARP inhibitor olaparib substantially delayed ovarian cancer from coming back after the first line of chemotherapy. The data may support olaparib as part of the standard of care for women with newly diagnosed ovarian cancer with a BRCA mutation.
		NCI-MATCH Update: More Labs, New Arms, and Initial Findings NCI’s Dr. Lyndsay Harris provides an update on the NCI-MATCH trial, including the opening of new trial treatment arms and the addition of new laboratories to perform testing on tumor samples of prospective trial participants.
Find NCI-Supported Clinical Trials Use our search form to find a clinical trial or other research study that may be right for you or a loved one.
Clinical Trials Information for Patients and Caregivers
Taking Part in Cancer Treatment Research Studies This booklet is for people with cancer who are thinking about joining a clinical trial, which is a research study that involves people. It is available for download in PDF, Kindle, and ePub formats.
		Cancer Clinical Trials at the National Institutes of Health Clinical Center The NIH Clinical Center in Bethesda, Maryland, is America’s largest hospital devoted entirely to clinical research. This page provides information about the Clinical Center, which NCI programs treat patients there, and how NCI doctors can work with your health care providers if you decide to join a clinical trial.
NCI-Supported Clinical Trials That Are Recruiting Patients
Three-Drug Combination for People with Smoldering Multiple Myeloma This phase 2 trial is testing carfilzomib, lenalidomide, and dexamethasone in treating people with smolder multiple myeloma, a precancerous condition that may develop into multiple myeloma. The current standard of care is close follow-up without treatment until multiple myeloma develops. However, researchers are studying possible treatments for smolder myeloma itself, including this drug combination, which has shown promising results in patients with symptomatic multiple myeloma.
Immunotoxin Followed by Immunotherapy in Malignant Mesothelioma This phase 2 trial tests how well treatment with an immunotoxin targeting mesothelin, a protein often found on certain types of cancer, followed by immunotherapy with pembrolizumab works in patients with malignant mesothelioma. Doctors want to see if using these agents in sequence will produce responses in patients not eligible for surgical resection of their cancer.
		Cellular Therapy for Patients with Ovarian Cancer or Peritoneal Mesothelioma  This phase 1 trial is studying cell therapy with MCY-M11, a chimeric antigen receptor (CAR) product designed to target mesothelin, for women with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or patients with peritoneal mesothelioma who experienced a recurrence after chemotherapy. Doctors want to determine the best dose and examine the safety of the cellular therapy when injected through the peritoneum for patients with metastatic or unresectable cancer.